Clinical trials: Disorder, Mood
Binge-Eating Disorder, Binge Eating
Binge Eating Anxiety and Mood
Binge Eating Disorder (BED) is the most common eating disorder, and currently, the best behavioral treatments only work for 40-60% of adults.
- Conditions
- Binge-Eating Disorder, Binge Eating, Anxiety Disorders, Mood Disorders
- Trial name
- BEAM (NCT04242550)
- Testing
- Executive Function- Enhanced CBT for BED (EF-BED+CBT), Cognitive Behavioral Therapy (CBT)
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of California, San Diego
Depression
An Investigation Into the Effects of Blueberry Anthocyanin on Cognitive Functioning and Mood in Adolescents.
The purpose of this study is to determine whether a 4-week dietary intervention with wild blueberry powder can have an effect on cognitive performance in participants aged between 13-17.
- Trial name
- NCT03119597
- Testing
- Wild Blueberry Powder-13g
- Where
- United Kingdom
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- University of Reading
Major Depressive Disorder, Major Depressive Episode
Mobile Observation Of Depression
The primary aim of this project is to test if OCOsense glasses can function as a digital phenotyping tool derived from behavioural and physiological signals related to facial expression and motion recorded using the glasses.
- Conditions
- Major Depressive Disorder, Major Depressive Episode, Bipolar Disorder
- Trial name
- MOOD (NCT05815459)
- Testing
- OCOsense
- Where
- United Kingdom
- Volunteers
- 84 people
- Sponsor
- Emteq Ltd
Anxiety Disorder/Anxiety State, Depressive Disorder/Psychology
Trial of the Youth Readiness Intervention
The research will first examine data obtained from YRI participants to investigate effects of the group sessions on psychosocial and functioning outcomes in youth.
- Conditions
- Anxiety Disorder/Anxiety State, Depressive Disorder/Psychology, Social Problems/Psychology, Stress, Psychological
- Trial name
- YRI (NCT01684488)
- Testing
- YRI, EducAid educational programming
- Where
- Sierra Leone
- Volunteers
- 443 people
- Sponsor
- Boston College
Agitation, Schizophrenia
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia
This is a definitive study to support the safety and efficacy evaluation of BXCL501 for the acute treatment of agitation in schizophrenia.
- Conditions
- Agitation, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder
- Trial name
- SERENITY I (NCT04268303)
- Testing
- Sublingual film containing dexmedetomidine (BXCL501)
- Where
- 15 sites in United States
- Volunteers
- 380 people
- Sponsor
- BioXcel Therapeutics Inc
Alcohol Dependence, Bipolar Disorder
Acamprosate vs. Placebo in Bipolar Alcoholics
To conduct a double-blind, randomized, placebo-controlled outpatient clinical trial of acamprosate in individuals with alcohol dependence and bipolar disorder who are also receiving mood stabilizing medication.
- Trial name
- NCT00466661
- Testing
- Acamprosate
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Medical University of South Carolina
Bipolar Disorder
Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder
The purpose of this study is to determine the efficacy and safety of ramelteon, once nightly before bedtime (QHS), sublingual (SL), in the maintenance treatment of Bipolar I Disorder in adult patients.
- Trial name
- NCT01467713
- Testing
- Ramelteon SL
- Where
- 156 sites in United States, Argentina and 3 more
- Volunteers
- 642 people
- Sponsor
- Takeda
Major Depressive Disorder
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD).
- Trial name
- NCT06058013
- Testing
- NMRA-335140
- Where
- 74 sites in United States, Brazil and 2 more
- Volunteers
- 430 people
- Sponsor
- Neumora Therapeutics, Inc.
Autism Spectrum Disorder, Depression
TMS for Adults With Autism and Depression
The goal of this proposal is to investigate whether a standard rTMS protocol for depression, including multiple sessions applied to left dorsolateral prefrontal cortex (DLPFC) results in reduction of depressive symptoms for adult…
- Conditions
- Autism Spectrum Disorder, Depression, Depressive Disorder, Major Depressive Disorder
- Trial name
- TAD (NCT02939560)
- Testing
- NeuroStar® TMS device (Neuronetics, Atlanta, GA)
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Depressive Disorder
Telephone-administered Relapse Prevention for Depression
This study determines the effectiveness of telephone-delivered cognitive-behavioral continuation therapy (T-CT) in comparison to usual care in people with recurrent or chronic depression.
- Trial name
- NaTel (NCT03219879)
- Testing
- Telephone-administered continuation therapy, Usual care
- Where
- 11 sites in Germany, Switzerland
- Volunteers
- 201 people
- Sponsor
- University of Zurich
MDD, Citalopram
Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression
Primarily, this study seeks to evaluate whether citalopram treatment is associated with an increase in the Glutamine (Gln)/Glutamate (Glu) ratio in the anterior cingulate cortex (ACC) from baseline to day 3 of treatment.
- Conditions
- MDD, Citalopram, Major Depressive Disorder
- Trial name
- NCT01557946
- Testing
- citalopram
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Mclean Hospital
Anxiety, Depressive Symptoms
Brief Digital CBT for Mood and Anxiety Symptoms in Acute Psychiatric Inpatients
A randomized control trial examining the feasibility, acceptability, and preliminary efficacy of providing access to the MindShift CBT mobile app via tablet for acute psychiatric inpatients.
- Conditions
- Anxiety, Depressive Symptoms, Distress, Emotional, Anxiety and Fear
- Trial name
- NCT04841603
- Testing
- Mindshift CBT, Treatment as Usual
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Centre for Addiction and Mental Health
Bipolar Disorder, Depressive Episode
Low-Dose Adjunctive Aripiprazole in the Treatment of Bipolar Depression: Double-Blind Placebo-Controlled Pilot Study
Aripiprazole is a new antipsychotic agent which possesses unique capabilities compared to other antipsychotic agents, especially because of its partial dopaminergic agonistic activity.
- Trial name
- NCT01520350
- Testing
- Low dose Adjunctive Aripiprazole
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Serge Beaulieu
Mood Disorders, Bipolar Disorder
Technology Enhanced Family Treatment
The investigators propose to enhance the scalability of family-focused therapy (FFT), a 12-session evidence-based therapy for youth at high risk for mood disorders, through augmentation with a novel mobile phone application…
- Conditions
- Mood Disorders, Bipolar Disorder, Major Depression
- Trial name
- NCT03913013
- Testing
- Family-Focused Treatment with MCC App
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of California, Los Angeles
Major Depressive Disorder, Treatment Resistant Depression
40 Hz Light Neurostimulation for Patients With Depression (FELIX)
Recent research in mice models of Alzheimer's disease (AD) has demonstrated that one hour per day of exposure to 40 Hz flickering light therapy can halt the disease's progression, and improve cognition and memory.
- Trial name
- NCT05680220
- Testing
- Neurostimulation System (NSS): Active Setting
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Klaus Martiny
Major Depressive Disorder
Bear Bile Pill as add-on the Treatment of MDD
This is a single-center, double blind, randomized, placebo-controlled, parallel group study of bear bile pill, as add-on therapy in MDD patients conducted in Shang Hai Mental Health Center.
- Trial name
- NCT04509882
- Testing
- bear bile pill
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Shanghai Mental Health Center
Depressive Disorder, Major
A Naturalistic Study of the Efficacy and Safety of Escitalopram in Treatment Resistant Depression
The primary objective of this multicenter study is to evaluate the efficacy of escitalopram in treatment resistant depression (TRD), assessed by 2 consecutive failed antidepressant treatments from different classes.
- Trial name
- NCT00220480
- Testing
- escitalopram
- Where
- 4 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Sheba Medical Center
Major Depressive Disorder
Development of Pregnenolone as a Treatment for Depression
Pregnenolone, an over-the-counter supplement, is a naturally occurring neurosteroid made in the adrenal glands and brain. Preclinical research suggests pregnenolone has antidepressant, cognitive enhancing, and neuroprotective…
- Trial name
- NCT03645096
- Testing
- Pregnenolone 500 mg, Pregnenolone 800 mg
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Texas Southwestern Medical Center
Major Depressive Disorder
Evaluation of the Brainsway Deep Transcranial Magnetic Stimulation (TMS) H-Coil in the Treatment of Major Depression Disorder
The purpose of the study is to evaluate the efficacy and safety of deep brain rTMS, (Transcranial Magnetic Stimulation), a new experimental procedure using the H-Coil, in subjects with Major Depressive Disorder that have been…
- Trial name
- NCT00927173
- Testing
- Brainsway H-Coil Deep TMS System
- Where
- 22 sites in United States, Canada and 3 more
- Volunteers
- 233 people
- Sponsor
- Brainsway
Major Depressive Disorder (MDD), Anxiety Disorders
Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment
This retrospective observational study examines the effects of psychedelic-assisted psychotherapy (PAP) with lysergic acid diethylamide (LSD) or psilocybin in patients with treatment-resistant depressive, anxiety, or addictive…
- Conditions
- Major Depressive Disorder (MDD), Anxiety Disorders, Substance Use Disorder (SUD), PTSD - Post Traumatic Stress Disorder
- Trial name
- NCT07164287
- Testing
- Lysergic Acid Diethylamide (LSD) or psilocybin
- Where
- Switzerland
- Volunteers
- 376 people
- Sponsor
- University Hospital, Geneva
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.